A new fund from the north
Hadean Ventures announced the launch of Hadean Capital I, a fund that will invest up to € 100 m in life science companies, with a particular focus on the Nordic region.
After the Life sciences investment group (LSP) has launched its €250m fund, it is the second closing of an European life science fund this month. Hadean Ventures announced the closing of Hadean Capital I, a new fund with a target size of €100m. A particular attention will be given to regions of Europe harbouring world class scientific communities, yet are under-served from a venture capital perspective, especially the Nordic region. The fund is supported by a consortium of blue chip fund investors, including Argentum, Saminvest, Gjensidigestiftelsen, OPF and Varner.
“In addition, the growing ecosystem and surge in entrepreneurship have created a very fertile ground for life science start-ups. In particular, the Nordic region has outstanding scientists, a stable, business friendly environment and a vibrant start-up community, yet very few life science specialist venture funds are on the ground. We see an exceptionally strong deal flow of high potential opportunities here,” states Ingrid Teigland Akay, Managing Partner of Hadean Ventures.